Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts

By                  

Oncology Reports, Vol. 33, Iss. 5, 2015-01 ,pp. : 2135-2142

Spandidos Publications

Access to resources Recommend Favorite

Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer

By Larsen Finn Ole   Pfeiffer Per   Nielsen Dorte   Skougaard Kristin   Qvortrup Camilla   Vistisen Kirsten   Fromm Anne-Lene   Jøørgensen Trine L.   Bjerregaard Jon K.   Hoegdall Estrid   Jensen Benny V.  

Acta Oncologica, Vol. 50, Iss. 4, 2011-05 ,pp. : 574-577

Informa Healthcare

Access to resources Recommend Favorite

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer

By Soeda Hiroshi   Shimodaira Hideki   Watanabe Mika   Suzuki Takao   Gamoh Makio   Mori Takahiro   Komine Keigo   Iwama Noriyuki   Kato Shunsuke   Ishioka Chikashi  

International Journal of Clinical Oncology, Vol. 18, Iss. 4, 2013-08 ,pp. : 670-677

Springer Publishing Company

Access to resources Recommend Favorite

Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival

By                                

Molecular and Clinical Oncology, Vol. 3, Iss. 5, 2015-01 ,pp. : 1053-1057

Science Publishers

Access to resources Recommend Favorite

Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer

By Degirmenci M.   Karaca B.   Gorumlu G.   Durusoy R.   Demir Piskin G.   Bozkurt M.   Cirak Y.   Tunali D.   Karabulut B.   Sanli U.   Uslu R.  

Medical Oncology, Vol. 27, Iss. 3, 2010-09 ,pp. : 585-591

Humana Press, Inc

Access to resources Recommend Favorite